In this articleAMGNFollow your favorite stocksCREATE FREE ACCOUNTThe Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023.Mario Tama | Getty ImagesAmgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity.The announcement is a setback for Amgen, which is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly, which some analysts say could be worth $100 billion by the end of the decade.

在这篇文章中，AMGNfollow your favorite stocksCREATE FREE account安进标志于2023年5月17日在加利福尼亚州千橡树安进总部外展示。马里奥·塔玛·盖蒂·萨进（Mario Tama | Getty ImagesAmgen）周四表示，将停止开发其实验性减肥药，而是继续开发其注射药和其他肥胖产品。这一宣布对安进来说是一个挫折，安进是几家争相加入由诺和诺德（Novo Nordisk）和礼来（Eli Lilly）主导的炙手可热的减肥药领域的制药商之一，一些分析师表示，到本世纪末，该领域的价值可能达到1000亿美元。

But the company has other opportunities to capture a slice of the market.'Given the profile we've seen with [the oral drug], we will not pursue further development. Instead, in obesity, we're differentially investing in MariTide and a number of preclinical assets,' Jay Bradner, Amgen's chief scientific officer, said during an earnings call Thursday.Amgen is developing an injectable obesity treatment called MariTide, which is an ongoing midstage trial in obese or overweight adults without diabetes.

但该公司还有其他机会获得市场份额。”鉴于我们已经看到[口服药物]的概况，我们不会寻求进一步的发展。安进首席科学官杰伊·布拉德纳（JayBradner）周四在一次财报电话会议上表示，相反，在肥胖症方面，我们正在对马里蒂德（MariTide）和一些临床前资产进行差异化投资。安进（Amgen）正在开发一种名为马里蒂德（MariTide）的可注射肥胖治疗药物，这是一项针对肥胖或超重的无糖尿病成年人的中期试验。

The company will release initial data from that study later this year and said it is working with regulators to plan a late-stage trial. Amgen is planning a stage two trial on the drug in diabetes treatment as well.Amgen also has other drugs in development for weight management. The drugmaker's oral drug, called AMG-786, is the second weight loss pill to be discontinued over the past year.Pfizer in December scrapped a twice-daily version of its obesity pill, danuglipron, after patients had a difficult time tolerating the drug in a midstage trial.

该公司将于今年晚些时候公布该研究的初步数据，并表示正在与监管机构合作，计划进行后期试验。安进（Amgen）也计划在糖尿病治疗中进行该药物的第二阶段试验。安进还有其他用于体重管理的药物正在开发中。该制药商的口服药AMG-786是去年第二种停止使用的减肥药。12月，辉瑞公司（Pfizer）在一项中期试验中，患者难以耐受该药物，因此取消了其每日两次的减肥药danuglipron。

The company is now developing a once-daily version of that drug.Investors are laser-focused on Amgen's pipeline of experimental weig.

该公司目前正在开发这种药物的每日一次的版本。投资者关注安进的实验性weig管道。